Annual Current Liabilities
$79.69 M
-$2.67 M-3.24%
December 31, 2023
Summary
- As of February 7, 2025, HRTX annual total current liabilities is $79.69 million, with the most recent change of -$2.67 million (-3.24%) on December 31, 2023.
- During the last 3 years, HRTX annual current liabilities has fallen by -$22.82 million (-22.26%).
- HRTX annual current liabilities is now -22.76% below its all-time high of $103.17 million, reached on December 31, 2017.
Performance
HRTX Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$85.54 M
+$5.23 M+6.51%
September 30, 2024
Summary
- As of February 7, 2025, HRTX quarterly total current liabilities is $85.54 million, with the most recent change of +$5.23 million (+6.51%) on September 30, 2024.
- Over the past year, HRTX quarterly current liabilities has increased by +$5.23 million (+6.51%).
- HRTX quarterly current liabilities is now -21.88% below its all-time high of $109.50 million, reached on June 30, 2022.
Performance
HRTX Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
HRTX Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -3.2% | +6.5% |
| 3 y3 years | -22.3% | +18.3% |
| 5 y5 years | -13.4% | -11.6% |
HRTX Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -3.2% | +12.1% | -21.9% | +20.4% |
| 5 y | 5-year | -22.3% | +12.1% | -21.9% | +20.4% |
| alltime | all time | -22.8% | >+9999.0% | -21.9% | >+9999.0% |
Heron Therapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $85.54 M(+6.5%) |
| Jun 2024 | - | $80.32 M(+6.6%) |
| Mar 2024 | - | $75.38 M(-5.4%) |
| Dec 2023 | $79.69 M(-3.2%) | $79.69 M(-0.1%) |
| Sep 2023 | - | $79.75 M(-8.0%) |
| Jun 2023 | - | $86.72 M(+11.3%) |
| Mar 2023 | - | $77.90 M(-5.4%) |
| Dec 2022 | $82.36 M(+15.9%) | $82.36 M(-12.3%) |
| Sep 2022 | - | $93.88 M(-14.3%) |
| Jun 2022 | - | $109.50 M(+17.7%) |
| Mar 2022 | - | $93.00 M(+30.9%) |
| Dec 2021 | $71.06 M(-30.7%) | $71.06 M(-1.7%) |
| Sep 2021 | - | $72.30 M(-12.0%) |
| Jun 2021 | - | $82.14 M(-18.6%) |
| Mar 2021 | - | $100.92 M(-1.5%) |
| Dec 2020 | $102.50 M(+6.0%) | $102.50 M(+5.0%) |
| Sep 2020 | - | $97.58 M(+5.3%) |
| Jun 2020 | - | $92.65 M(-4.3%) |
| Mar 2020 | - | $96.77 M(+0.1%) |
| Dec 2019 | $96.70 M(+5.1%) | $96.70 M(-0.0%) |
| Sep 2019 | - | $96.74 M(+1.8%) |
| Jun 2019 | - | $95.06 M(+3.0%) |
| Mar 2019 | - | $92.26 M(+0.3%) |
| Dec 2018 | $92.02 M(-10.8%) | $92.02 M(+43.6%) |
| Sep 2018 | - | $64.09 M(-18.5%) |
| Jun 2018 | - | $78.67 M(-13.7%) |
| Mar 2018 | - | $91.18 M(-11.6%) |
| Dec 2017 | $103.17 M(+166.4%) | $103.17 M(+94.1%) |
| Sep 2017 | - | $53.14 M(+10.0%) |
| Jun 2017 | - | $48.30 M(+29.1%) |
| Mar 2017 | - | $37.40 M(-3.4%) |
| Dec 2016 | $38.73 M(+96.3%) | $38.73 M(+25.2%) |
| Sep 2016 | - | $30.93 M(+10.9%) |
| Jun 2016 | - | $27.89 M(+45.5%) |
| Mar 2016 | - | $19.17 M(-2.9%) |
| Dec 2015 | $19.73 M(+44.9%) | $19.73 M(+20.0%) |
| Sep 2015 | - | $16.45 M(-0.8%) |
| Jun 2015 | - | $16.59 M(+42.7%) |
| Mar 2015 | - | $11.63 M(-14.6%) |
| Dec 2014 | $13.62 M(+94.8%) | $13.62 M(+20.8%) |
| Sep 2014 | - | $11.27 M(+4.5%) |
| Jun 2014 | - | $10.79 M(+46.2%) |
| Mar 2014 | - | $7.38 M(+5.6%) |
| Dec 2013 | $6.99 M(+68.3%) | $6.99 M(+27.2%) |
| Sep 2013 | - | $5.50 M(-42.7%) |
| Jun 2013 | - | $9.59 M(+26.3%) |
| Mar 2013 | - | $7.60 M(+82.9%) |
| Dec 2012 | $4.15 M(+12.5%) | $4.15 M(-2.1%) |
| Sep 2012 | - | $4.24 M(+36.2%) |
| Jun 2012 | - | $3.12 M(-7.3%) |
| Mar 2012 | - | $3.36 M(-9.0%) |
| Dec 2011 | $3.69 M(+136.7%) | $3.69 M(+45.4%) |
| Sep 2011 | - | $2.54 M(-20.7%) |
| Jun 2011 | - | $3.20 M(+90.1%) |
| Mar 2011 | - | $1.69 M(+8.0%) |
| Dec 2010 | $1.56 M(-17.3%) | $1.56 M(+14.0%) |
| Sep 2010 | - | $1.37 M(-48.3%) |
| Jun 2010 | - | $2.65 M(+33.7%) |
| Mar 2010 | - | $1.98 M(+5.0%) |
| Dec 2009 | $1.89 M(-40.8%) | $1.89 M(-21.5%) |
| Sep 2009 | - | $2.40 M(-0.4%) |
| Jun 2009 | - | $2.41 M(-12.7%) |
| Mar 2009 | - | $2.76 M(-13.3%) |
| Dec 2008 | $3.19 M(-48.7%) | $3.19 M(-44.0%) |
| Sep 2008 | - | $5.69 M(+11.3%) |
| Jun 2008 | - | $5.12 M(-7.1%) |
| Mar 2008 | - | $5.51 M(-11.3%) |
| Dec 2007 | $6.21 M(+48.1%) | $6.21 M(+74.5%) |
| Sep 2007 | - | $3.56 M(+0.1%) |
| Jun 2007 | - | $3.55 M(-4.9%) |
| Mar 2007 | - | $3.73 M(-10.9%) |
| Dec 2006 | $4.19 M | $4.19 M(+73.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2006 | - | $2.42 M(+5.2%) |
| Jun 2006 | - | $2.30 M(+3.7%) |
| Mar 2006 | - | $2.22 M(-19.8%) |
| Dec 2005 | $2.77 M(-3.3%) | $2.77 M(+10.3%) |
| Sep 2005 | - | $2.51 M(+3.2%) |
| Jun 2005 | - | $2.43 M(+24.2%) |
| Mar 2005 | - | $1.96 M(-31.6%) |
| Dec 2004 | $2.86 M(+51.2%) | $2.86 M(+27.0%) |
| Sep 2004 | - | $2.25 M(+22.9%) |
| Jun 2004 | - | $1.83 M(-27.2%) |
| Mar 2004 | - | $2.52 M(+33.1%) |
| Dec 2003 | $1.89 M(-4.3%) | $1.89 M(-6.7%) |
| Sep 2003 | - | $2.03 M(-6.0%) |
| Jun 2003 | - | $2.16 M(-10.9%) |
| Mar 2003 | - | $2.42 M(+22.4%) |
| Dec 2002 | $1.98 M(-44.3%) | $1.98 M(-21.1%) |
| Sep 2002 | - | $2.50 M(-14.8%) |
| Jun 2002 | - | $2.94 M(+5.0%) |
| Mar 2002 | - | $2.80 M(-21.1%) |
| Dec 2001 | $3.55 M(-28.5%) | $3.55 M(+13.0%) |
| Sep 2001 | - | $3.14 M(-22.2%) |
| Jun 2001 | - | $4.04 M(+3.3%) |
| Mar 2001 | - | $3.91 M(-21.2%) |
| Dec 2000 | $4.96 M(+31.6%) | $4.96 M(-9.2%) |
| Sep 2000 | - | $5.47 M(+38.2%) |
| Jun 2000 | - | $3.96 M(+3.3%) |
| Mar 2000 | - | $3.83 M(+1.5%) |
| Dec 1999 | $3.77 M(-53.4%) | $3.77 M(-21.4%) |
| Sep 1999 | - | $4.80 M(+14.3%) |
| Jun 1999 | - | $4.20 M(-25.0%) |
| Mar 1999 | - | $5.60 M(-30.9%) |
| Dec 1998 | $8.10 M(-11.0%) | $8.10 M(-10.0%) |
| Sep 1998 | - | $9.00 M(-23.1%) |
| Jun 1998 | - | $11.70 M(-4.1%) |
| Mar 1998 | - | $12.20 M(+34.1%) |
| Dec 1997 | $9.10 M(+15.2%) | $9.10 M(-10.8%) |
| Sep 1997 | - | $10.20 M(+5.2%) |
| Jun 1997 | - | $9.70 M(+9.0%) |
| Mar 1997 | - | $8.90 M(+12.7%) |
| Dec 1996 | $7.90 M(-31.3%) | $7.90 M(-18.6%) |
| Sep 1996 | - | $9.70 M(-3.0%) |
| Jun 1996 | - | $10.00 M(+3.1%) |
| Mar 1996 | - | $9.70 M(-15.7%) |
| Dec 1995 | $11.50 M(+7.5%) | $11.50 M(-4.2%) |
| Sep 1995 | - | $12.00 M(-15.5%) |
| Jun 1995 | - | $14.20 M(-1.4%) |
| Mar 1995 | - | $14.40 M(+34.6%) |
| Dec 1994 | $10.70 M(+1.9%) | $10.70 M(+9.2%) |
| Sep 1994 | - | $9.80 M(-22.8%) |
| Jun 1994 | - | $12.70 M(-8.6%) |
| Mar 1994 | - | $13.90 M(+32.4%) |
| Dec 1993 | $10.50 M(+138.6%) | $10.50 M(+18.0%) |
| Sep 1993 | - | $8.90 M(-27.0%) |
| Jun 1993 | - | $12.20 M(+183.7%) |
| Mar 1993 | - | $4.30 M(-2.3%) |
| Dec 1992 | $4.40 M(+83.3%) | $4.40 M(+4.8%) |
| Sep 1992 | - | $4.20 M(+100.0%) |
| Jun 1992 | - | $2.10 M(+75.0%) |
| Mar 1992 | - | $1.20 M(-50.0%) |
| Dec 1991 | $2.40 M(+4.3%) | $2.40 M(+14.3%) |
| Sep 1991 | - | $2.10 M(0.0%) |
| Jun 1991 | - | $2.10 M(0.0%) |
| Mar 1991 | - | $2.10 M(-8.7%) |
| Dec 1990 | $2.30 M(+228.6%) | $2.30 M(-39.5%) |
| Sep 1990 | - | $3.80 M(+2.7%) |
| Jun 1990 | - | $3.70 M(+516.7%) |
| Mar 1990 | - | $600.00 K(-14.3%) |
| Dec 1989 | $700.00 K(+16.7%) | $700.00 K(0.0%) |
| Sep 1989 | - | $700.00 K(-12.5%) |
| Jun 1989 | - | $800.00 K(+33.3%) |
| Dec 1988 | $600.00 K(-14.3%) | $600.00 K(-14.3%) |
| Dec 1987 | $700.00 K | $700.00 K |
FAQ
- What is Heron Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Heron Therapeutics?
- What is Heron Therapeutics annual current liabilities year-on-year change?
- What is Heron Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Heron Therapeutics?
- What is Heron Therapeutics quarterly current liabilities year-on-year change?
What is Heron Therapeutics annual total current liabilities?
The current annual current liabilities of HRTX is $79.69 M
What is the all time high annual current liabilities for Heron Therapeutics?
Heron Therapeutics all-time high annual total current liabilities is $103.17 M
What is Heron Therapeutics annual current liabilities year-on-year change?
Over the past year, HRTX annual total current liabilities has changed by -$2.67 M (-3.24%)
What is Heron Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of HRTX is $85.54 M
What is the all time high quarterly current liabilities for Heron Therapeutics?
Heron Therapeutics all-time high quarterly total current liabilities is $109.50 M
What is Heron Therapeutics quarterly current liabilities year-on-year change?
Over the past year, HRTX quarterly total current liabilities has changed by +$5.23 M (+6.51%)